12:21 AM EST, 11/02/2026 (MT Newswires) -- Stratec (SBS.F) agreed to sell its subsidiary Diatron MI to a consortium of Indian investors for 10 million euros, plus potential earn-out payments. The German biomedical technology company said Oct. 30 the transaction covers Diatron's hematology and clinical chemistry products, while the original equipment manufacturing business in molecular and immunodiagnostics will remain with Stratec. The transaction is expected to close in the fourth quarter.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.